August 7, 2019Open Access
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Structured PICO
Does volanesorsen reduce triglyceride levels in patients with familial chylomicronemia syndrome?
P
Population
Patients with familial chylomicronemia syndrome
I
Intervention
Volanesorsen
O
Outcome
Triglyceride levelssurrogate
Volanesorsen effectively lowers triglyceride levels in patients with familial chylomicronemia syndrome, though it is associated with thrombocytopenia and injection-site reactions.
Abstract
Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Joseph L. Witztum
Preventive Cardiology
Daniel Gaudet
Preventive Cardiology
S
Steven D. Freedman
Beth Israel Deaconess Medical Center
Journals
New England Journal of Medicine
Actions
Institutions
University of California, San Diego
Massachusetts General Hospital
Sorbonne Université
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...